NCT01983462终止2 期
Vascular Dysfunction in Human Obesity Hypertension: Integrative Role of Sympathetic and Renin-Angiotensin Systems
Gary L. Pierce1 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2013年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Aortic Stiffness
研究概览
简要总结
The purpose of the study is to test the effects of blocking sympathetic nerve activity with a drug called clonidine on blood vessel function and muscle nerve activity in adults who are obese and have high blood pressure.
The cohort of subjects will consist of 69 healthy young men and women age 18-79 years who are obese, defined as a body mass index > or = to 30 kg/m2, who have untreated systolic hypertension (systolic blood pressure > or = to 130 - <180 mmHg- average of at least 3 measurements 2 min apart after 10 min seated resting position). These 69 subjects will then be randomized to 3 treatment arms: clonidine (0.1 mg/day), hydrochlorothiazide (25 mg/day) or placebo for 4 weeks in years 1 and 2. All tablets will be encapsulated by to look identical. Subjects will randomly (1:1:1) receive one of the following combinations in a double-blind, placebo-controlled design:
- Oral clonidine (0.1 mg twice/day)
- Oral hydrochlorothiazide (12.5 mg twice/day)
- Oral placebo
I
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures.
- •Systolic blood pressure >/= 130 mmHg and <180 mmHg
- •Age is > or = 18 and < or = 79 years of age
- •Weight stable (+/- 5 lbs) for the previous 3 months
- •Healthy, as determined by health history questionnaire, blood chemistries, 12-lead ECG
- •Blood chemistries indicative of normal renal (creatinine <2.0 mg/dl), liver (<3 times upper limit for ALT, AST), and thyroid function (TSH between 0.4 - 5.0 mU/L)
- •If currently receiving treatment with or taking any of the following supplements, be willing and able to discontinue taking them for 2 weeks prior and throughout the treatment period: Vitamin C, E or other multivitamins containing vitamin C or E; or omega-3 fatty acids.
- •No history of cardiovascular disease (e.g., heart attack, stroke, heart failure, valvular heart disease, cardiomyopathy), Type 1 or Type 2 diabetes, or peripheral arterial disease
- •Non-smokers, defined as no history of smoking or no smoking for at least the past 1 year
- •Normal resting 12-lead ECG (no evidence of myocardial infarction, left ventricular hypertrophy, left-bundle branch block, 2nd or 3rd degree AV block, atrial fibrillation/flutter)
排除标准
- •Systolic blood pressure >/=180 mmHg or diastolic blood pressure >110 mmHg
- •History of cardiovascular disease such as heart angioplasty/stent or bypass surgery, myocardial infarction, stroke, heart failure with or without left ventricular ejection fraction <40%, cardiomyopathy, valvular heart disease, cardiomyopathy, heart transplantation, Type 2 and Type 1 diabetes
- •Smoking or history of smoking within past one year
- •History of gastric ulcers, bleeding disorders, dyspepsia, severe gastroesophageal reflux disease (GERD), or metabolic acidosis
- •History of chronic obstructive pulmonary disease (COPD)
- •Abnormal resting 12-lead ECG (e.g., evidence of myocardial infarction, left ventricular hypertrophy, left-bundle branch block, 2nd or 3rd degree AV block, atrial fibrillation/flutter)
- •Serious neurologic disorders including seizures
- •History of renal failure, dialysis or kidney transplant
- •Serum creatinine > 2.0 mg/dL, or hepatic enzyme (ALT/AST) concentrations > 3 times the upper limit of normal
- •History of HIV infection, hepatic cirrhosis, other preexisting liver disease, or positive HIV, Hepatitis B or C test at screening.
- •Use of any investigational product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
- •History of recent chicken pox, shingles or influenza (ie., risk of Reye's syndrome)
- •Recent flu-like symptoms within the past 2 weeks
- •Pregnant or breastfeeding at screening, or planning to become pregnant (self or partner) at any time during the study. A urinary pregnancy test will be done on all females. If test is positive, the subject will be excluded.
- •Women with history of hormone replacement therapy within the past 6 months
- •History of rheumatoid arthritis, Grave's disease, systemic lupus erythematosis, and Wegener's granulomatosis;
- •Taking lipid lowering (e.g., statins, niacin), glycemic control (e.g. metformin, insulin), anticoagulation, anti-seizure, anti-depression or antipsychotic agents
- •History of co-morbid condition that would limit life expectancy to < 6 months.
- •Taking chronic non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, indomethacin, naproxen, acetaminophen (Tylenol), ibuprofen (Advil, Motrin) and not able or willing to go off of for 2 weeks prior and during the study
- •Taking cox-2 inhibitors (Celebrex, Vioxx, etc) or allopurinol (Zyloprim, Lopurin, Allopurin)
- •Taking blood thinners such as coumadin (Warfarin), enoxaparin (Lovenox); clopidogrel (Plavix); dipyridamole (Persantine); heparin;
- •Taking diabetic medications (Metformin, glyburide, insulin, etc.), thiazolidinediones (Avandia, Rezulin, Actos);
- •Taking steroids or biologics : corticosteroids (prednisone); methotrexate, infliximab (Remicade), etanercept (Enbrel); anakinra;
- •Taking thyroid medications such as levothyroxine (Levoxyl, Synthroid, Levoxyl, Unithroid); Levodopa;
- •Taking Phosphodiesterase (PDE) 5 inhibitors (e.g., Viagra®, Cialis®, Levitra®, or Revatio®); PDE 3 inhibitors (e.g., cilostazol, milrinone, or vesnarinone); lithium
- •May participate if no use of the following medications in the 48 hours prior to experimental visits: naproxen (Aleve), acetaminophen (Tylenol), ibuprofen (Advil, Motrin), other any non-steroidal anti-inflammatory drugs (NSAIDS)
- •Vulnerable populations (prisoners, etc.)
- •Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study.
- •History of alcohol abuse or >10 alcoholic units per week (1 unit= 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 oz alcohol)
- •On weight loss drugs (e.g., Xenical (orlistat), Meridia (sibutramine), Acutrim (phenylpropanol-amine), or similar over-the-counter medications) within 3 months of screening
- •Any surgery within 30 days of screening
研究组 & 干预措施
Clonidine
Experimental
Oral 0.2 mg/day (0.1 mg bid)for 4 weeks
干预措施: Clonidine (Drug)
Hydrochlorothiazide
Active Comparator
Oral, 12.5 mg/day qd, 4 weeks
干预措施: Hydrochlorothiazide (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Aortic Stiffness
时间窗: 4 weeks
Carotid-femoral pulse wave velocity (PWV)
次要结局
- 24 Hour Average Systolic Blood Pressure(4 weeks)
研究者
Gary L. Pierce
Assistant Professor
University of Iowa
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)Cardiovascular DiseasesHypertensionNCT04715022University of Kansas Medical Center23
撤回
3 期
Mechanism of Masked Hypertension - InterventionMasked HypertensionNCT04121299University of Alabama at Birmingham
终止
4 期
Sympathetic Nervous System Modulation in HypertensionHypertensionNCT00491387University of Cincinnati24
招募中
1 期
Sympathetic Mechanisms in Obesity-Crossover DesignObesityHypertensionNCT05312892Vanderbilt University Medical Center12
进行中（未招募）
1 期
Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in ObesityHealthyInsulin ResistanceObesityNCT03318094Vanderbilt University Medical Center36